Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: The case for purging?

Bone Marrow Transplantation

Volumn 23, Issue 7, 1999, Pages 681-686

  Jacquy, C ^a   Lambert, F ^b   Soree, A ^a   Van Daele, S ^b   Heusterspreute, M ^b   Bosly, A ^b   Ferrant, A ^b   Parma, J ^a   Bron, D ^a   Martiat, P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Lymphoma; PBSC; Residual disease

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOGRAFT; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLONOGENESIS; CONTAMINATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0032918930     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701637     Document Type: Article

References (29)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
2. Weisenburger DD, Armitage JO. Mantle cell lymphoma, an entity comes of age. Blood 1996; 87: 4483-4490.
3. Zucca E, Soldati G, Schlegelberger B et al. Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma. Br J Haematol 1995; 89: 665-671.
4. Bigoni R, Negrini M, Veronese ML et al. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 1996; 13: 797-803.
5. Uchimaru K, Taniguchi T, Yoshikawa M et al. Detection of Cyclin D1 overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood 1997; 89: 965-974.
6. Bosch F, Lopez-Guillermo A, Campo E et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-575.
7. Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997; 99: 842-847.
8. Segal GH, Masih AS, Fox AC et al. CDS-expressing B cell non Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995; 85: 1570-1577.
9. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
10. Takvorian T, Canellos G, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with poor prognosis. New Engl J Med 1987; 316: 1499-1506.
11. Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 97-99.
12. Kroger N, Hoffknecht M, Dreger P et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998; 21: 55-57.
13. Blay JY, Sebban C, Surbiguet C et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998; 21: 51-54.
14. Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16: 13-18.
15. Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-4221.
16. Ketterer N, Salles G, Espinouse D et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8: 701-704.
17. Dreger P, von Neuhoff N, Kuse R et al. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997; 8: 401-403.
18. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin lymphomas treated with high-dose chemotherapy and peripheral blood progenitor autografting. Blood 1997; 89: 724-731.
19. Stewart DA, Vose JM, Weisenburger DD et al. The role of high dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263-269.
20. Aubin J, Davi F, Nguyen-Salomon F et al. Description of a novel FR1 IGH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 1995; 9: 470-479.
21. Nizet Y, Martiat P, Vaerman JL et al. Follow-up of residual disease (MRD) in B lineage acute leukaemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 1991; 79: 205-210.
22. Nizet Y, Van Daele S, Lewalle P et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IGH probes and the polymerase chain reaction. Blood 1993; 82: 1618-1625.
23. Jacquy C, Delepaut B, Van Daele S et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997; 98: 140-146.
24. Heusterspreute M, Derclaye I, Gala JL et al. Beta thalassemia in indigenous Belgian families: identification of a novel mutation. Hum Genet 1996; 98: 77-79.
25. Landman-Parker J, Aubin J, Delabesse E et al. Simplified strategies for minimal residual disease detection in B-cell precursor acute lymphoblastic leukaemia. Br J Haematol 1996; 95: 281-290.
26. Shiach CR, Evans PA, Short MA et al. Detection and accurate sizing of PCR products by automated scanning; improved detection of immunoglobulin gene rearrangements in ALL. Br J Haematol 1993; 85: 431-433.
27. Sykes PJ, Neoh SH, Brisco MJ et al. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992; 13: 444-448.
28. Ouspenskaia M, Johnston D, Roberts W et al. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia 1995; 9: 321-328.
29. Kurokawa T, Kinoshita T, Murate T et al. Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma. Br J Haematol 1997; 98: 408-412.